þ CD25 þ regulatory T (Treg) cells engage in the maintenance of immunological self-tolerance and homeostasis by limiting aberrant or excessive inflammation. The transcription factor forkhead box P3 (FOXP3) is critical for the development and function of Treg cells. The differentiation of the Treg cell lineage is not terminal, as developmental and functional plasticity occur through the sensing of inflammatory signals in the periphery. Here, we review the recent progress in our understanding of the molecular mechanisms underlying the regulation and functional plasticity of CD4 þ CD25 þ FOXP3 þ Treg cells, through the perturbation of FOXP3 and its complex at a transcriptional, translational and post-translational level.
Forkhead box P3
þ (FOXP3 in human, Foxp3 in mice; hereafter referred to as FOXP3 unless specified) regulatory T (Treg) cells have an important role during immune homeostasis through the maintenance of immune tolerance and prevention of inflammatory disease. 1 The transcription factor FOXP3 is essential for the development and function of Treg cells. 2 The loss of expression and mutations of FOXP3 lead to the development of chronic autoimmunity and is presented as the scurfy phenotype in mice 3 and X-linked autoimmunity-allergic dysregulation and immunodysregulation, polyendocrinopathy and enteropathy, X-linked syndrome in humans. 4 Although Treg cells are essential for the tolerance of commensal microbiota in the gut, 5 an excessive Treg cell response may facilitate tumor growth and chronic infection by limiting anti-tumor or anti-pathogenic immune responses, respectively. 6, 7 Thus, Treg cell function must be tightly controlled to heighten or dampen inflammation according to the desired response. Recent studies have also identified FOXP3 expression in epithelial cells, multipotent mesenchymal stromal cells, invariant natural killer T cells and macrophages, [8] [9] [10] but CD4 þ CD25 þ T lymphocytes remain the most characterized cell type. 11 There are two major subtypes of Treg cells according to their differentiation origin; natural Treg (nTreg) and induced Treg (iTreg) cells differentiate and adopt FOXP3 expression in the thymus and periphery, respectively. Naïve T cells differentiate into iTreg cells in the presence of IL-2, transforming growth factor (TGF)-b and stimulation through the T-cell receptor (TcR). [12] [13] [14] [15] TGF-b is also required for IL-6-dependent expression of the transcription factor RORgt and inhibition of FOXP3 expression during the generation of Th17 cells from naïve T cells. [16] [17] [18] [19] [20] However, the expression of FOXP3 and RORgt are not always mutually exclusive, as Foxp3 þ T cells in the gut have been shown to co-express high levels of RORgt and concurrently secrete IL-17. [21] [22] [23] Human CD4 þ CD25 À T cells can also transiently express FOXP3 after TcR stimulation without the requirement of other extrinsic signals, but whether or not they are suppressive during this period is still under debate. [24] [25] [26] [27] [28] [29] [30] The instability and plasticity of Treg cells A number of recent studies have shown that Treg cells harbor the propensity to reprogram into proinflammatory cells. [31] [32] [33] [34] [35] [36] [37] [38] [39] For instance, Th1-like FOXP3 þ Treg cells have been identified in human subjects with multiple sclerosis. 40 The evolutionary advantage of this process could be explained during inflammation, whereby the suppressive nature of Treg cells should be limited for protective and proinflammatory responses to ensue.
As Foxp3 expression is required for the maintenance of Treg cell identity and function, 41 recent investigations have looked into the in vivo role of Foxp3 expression for the reprogramming of Treg cells. 32, 33 Rudensky and colleagues 32 used GFP-Cre knock-in mice driven off the Foxp3 promoter, crossed with R26-YFP mice to fluorescently track all the cells that express or had previously expressed Foxp3 in vivo. This system utilized a GFP-Cre mutated estrogen receptor fusion protein so that the Foxp3 driven Cre could be induced for its translocation into the nucleus after treatment with tamoxifen. Here, they found that Foxp3 expression in Treg cells was rather stable (only B4% cells were YFP þ and GFP À ) when incubated under a long-term physiological setting in mice, with or without viral challenge. This observation should interest those who are investigating the use of ex vivo expanded nTreg and iTreg cells for the treatment of autoimmune disease. [42] [43] [44] These studies suggest that the use of ex vivo expanded and infused Treg cells can provide long-term protective effects in humans. However, other studies have indicated that under a physiological setting Treg cells may not be terminally differentiated, and that the instability of Treg cell function is driven by the local cytokine milieu and the loss of Foxp3 expression in Treg cells.
In contrast to the above, Bluestone and colleagues 127, [131] [132] [133] used a bacterial artificial chromosome Foxp3-GFP-Cre system with R26-YFP, in which they observed the downregulation of Foxp3 expression in a significant proportion of YFP þ T cells (B15% cells were YFP þ and GFP À ); these T cells exhibited an activatedmemory T-cell phenotype, produced inflammatory cytokines and were dubbed 'ex-Foxp3' T cells. When these 'ex-Foxp3' T cells were transferred into non-obese diabetic Rag2
À/À mice, they rapidly developed diabetes. Moreover, only a small percentage of YFP þ cells (0.5%) were observed after the transfer of YFP À T cells into recipient mice, which suggests that the 'ex-Foxp3' T-cell population was largely derived from nTreg cells. 33 Therefore, the depletion of Foxp3 in Treg cells may have resulted in the conversion of Treg cells into autoaggressive lymphocytes ('ex-Treg' cells), a trait that was not observed in the B4% of the 'ex-Foxp3' T cells in the study using tamoxifen-treated mice. 32 It should be noted that the loss of Foxp3 in this system could be attributed to the transient expressers of Foxp3 rather than the committed immunoregulators. In the bacterial artificial chromosomes system, Cre is driven from birth and induces YFP expression in all the cells that have expressed Foxp3 at some point, whereas the tamoxifen study could have labeled a high Foxp3-expressing and more stable proportion of the overall Foxp3 þ population. This supports the notion that a proportion of Foxp3 þ Treg cells can convert into 'ex-Treg' cells due to their natural heterogeneity, as not all FOXP3
þ Treg cells are fully committed to the Treg cell lineage. 45 In any case, the populations that were monitored in these two reports were intrinsically different, and may account for the differences in their findings. Another study that focused on characterizing the progenitors of CD4 53 found that IL-6 signals affected Foxp3 expression and function in nTreg but not iTreg cells due to the downregulation of the IL-6 receptor (IL-6R) after IL-2 and TGF-b treatment (used to convert naive T cells into iTreg cells). However, the treatment of nTreg cells with IL-2 and TGF-b, but not IL-2 alone, also induces the downregulation of the IL-6R in nTreg cells to render them insensitive to IL-6 stimulation. More recently, an active derivation of vitamin A, all-trans RA, has also been shown to protect nTreg cells from their conversion into Th17 cells 54, 55 due to the downregulation of the IL-6R. 55, 56 However, Dong and colleagues 57 found that iTreg cells were susceptible to IL-6-induced Foxp3 depletion in Treg cells even after TGF-b treatment. It is unclear as to why these two reports differ in their characterization of how iTreg cells convert into Th17 cells-it may be due to the different systems used, but what seems clear is that the expression of IL-6R on Treg cells has a role in their sensitivity to reprogramming via IL-6R signaling. We have recently developed a system to test the direct signals required for IL-6-mediated downregulation of FOXP3 expression at the protein level. Here, we found that when FOXP3 is overexpressed in FOXP3 À cells, FOXP3 could be directed for degradation via IL-6 signals (unpublished data). Thus, the mechanism of 'ex-Foxp3' T-cell generation via proinflammatory cytokines, such as IL-6, may not only occur at the transcriptional level (see below) but also at the protein level. 62 Therefore, the expression of T-bet was found to be required for the homeostasis and function of Treg cells during type 1 inflammation. 62 IFN regulatory factor 4 is a transcription factor responsible for the expression of IL-4 in Th2 cells. The co-expression of Foxp3 and IFN regulatory factor 4 in Treg cells endows them with the ability to suppress Th2 responses. 63 The overlapping expression of T-bet and IFN regulatory factor 4 with Foxp3 may be necessary for the rapid response of Treg cells to suppress excessive inflammation by Th cells. Finally, Bcl6, a transcription factor required for the generation of T-follicular helper cells and the expression of CXCR5, has been found to be responsible for the generation of CXCR5 þ Treg cells, which can inhibit germinal center reactions to regulate humoral immunity. 64, 65 Considering the above, it would seem inappropriate that these reprogrammed cells be named 'ex-Treg' cells, as their further differentiation determines the target for suppression, but this name may be fitting for those Treg cells that have lost their ability to suppress immune responses.
The expression or loss of expression of Foxp3 in Foxp3 þ Treg cells may coincide with the expression of Th-specific transcription factors or cytokines, but it remains unclear as to how these populations differ. A recent investigation has shed some light on this dichotomy by demonstrating how Foxp3 þ IFN-g þ T cells retain regulatory functions, but are able to differentiate further into single positive IFN-g þ T cells; 66 this mechanism could be attributed to the increased activity of Stat1, which was observed in miR-146a knockout Treg cells (see below). 67 Therefore, there may be a threshold of expression and/or activation of Th-specific transcription factors in Foxp3 þ Treg cells that allow them to convert from a Th-specific suppressor to a contributor of proinflammatory responses. However, the exact mechanisms and co-stimulatory signals that are required for this conversion have yet to be characterized. Moreover, it may be possible that Foxp3 þ T cells that co-express Th markers or are fully converted into Th cells may arise from specific pools of Treg cells that are more or less committed toward the Treg lineage, respectively. 
Epigenetic and transcriptional regulation of FOXP3
The FOXP3 gene is comprised of 11 exons, and its promoter is located À6221 bp upstream of the translation start site. The 5 0 -untranslated region is interrupted by a 6000-bp intron, which contains a splice donor site at the 5 0 -end and splice acceptor site at the 3 0 -end, 22 bp upstream of the translation start site. The FOXP3 gene promoter is highly conserved between humans, mice and rats. 68 Mantel et al. 68 used a reporter assay to analyze the human FOXP3 functional promoter and found that the activation responsive element of the FOXP3 promoter is located within the À511 to À307 region. The basal promoter contains six nuclear factors of activated T cells (NFAT) and activator protein-1 (AP-1) binding sites, which positively regulates the transactivation of the FOXP3 promoter after the triggering of the TcR. 68 The regulatory regions of Foxp3 also contains three conserved noncoding DNA sequence elements (CNS1, 2 and 3), 69 also known as enhancers. 70, 71 Using a mouse knockout strategy deficient in these CNS regions, it was found that CNS1 controls peripheral, but not thymic, induction of Foxp3 expression; CNS2 controls the heritable maintenance of Foxp3 expression; and c-Rel binds to CNS3 and facilitates Foxp3 induction during thymic and peripheral Treg cell differentiation. 69 The epigenetic state of the Foxp3 locus determines the transcriptional activity of the Foxp3 gene. Huehn and colleagues 72, 73 found that an enhancer region (CNS2) of the Foxp3 gene contained CpG motifs (also called the 'Treg-specific demethylation region' (TSDR)), which were fully demethylated in nTreg cells, partially demethylated in TGF-b-polarized iTreg cells and methylated in naïve and Th cells. These findings suggest that the epigenetic modification of the Foxp3 gene is critical for the stable expression and suppressive function of Treg cells. These observations have also been confirmed in cord blood Treg cells 74 and peripheral Treg cells 75 in humans, where the latter transient expressers of FOXP3 bear a partially methylated TSDR. 75 Consistent with this FOXP3 þ regulatory T cell regulation and plasticity Y Gao et al notion, a TcR response element was found in the first intron of the Foxp3 gene that is located within this CNS region 76 and also Est-1 binding sites, which are important for positively regulating Foxp3 transcription. 77, 78 The TSDR also overlaps with the binding site for the transcription factor cyclic AMP (cAMP) response element-binding, where an increase in TSDR methylation negatively correlates with cAMP response elementbinding and Foxp3 expression. 70 Moreover, the treatment of Treg cells using 5 0 -azacytidine, a DNA methyltransferase inhibitor, leads to the rapid passive demethylation of DNA in this region to increase Foxp3 expression, even in the absence of TGF-b. 70 Naïve T cells that are treated with DNA methyltransferase inhibitors and TGF-b can convert into Treg cells, with high Foxp3 expression and stable suppressive function. 79 Conversely, IL-6 can reduce Foxp3 expression and increase TSDR methylation in nTreg cells. 79 More recently, the SUMO E3 ligase PIAS1 has been shown to recruit DNA methylases and heterochromatin protein 1 to reduce Foxp3 promoter accessibility. 80 The elucidation of how Treg cell instability relates to the known properties of epigenetic regulation of the Foxp3 locus could therefore provide important insights into the reversibility of 'ex-Foxp3' T cells. Additionally, any future therapies involving the use of the ex vivo expanded and infused Treg cells in humans 42, 43 may require further testing of their epigenetic state to ensure that the most stable Treg cells are utilized.
The binding of transcription factors to the promoter regions of Foxp3 serve to augment or inhibit the transcription of this gene. Even though the epigenetic modifications detailed above offer us an indication of the basal stability and conformation of the Foxp3 gene, the transient changes in expression and activity of transcription factors ultimately determine the outcome of gene transcription. Smad3 and NFAT can activate a Foxp3 enhancer (CNS1). 71 The binding of both of these factors increases the acetylation of histones (such as histone 4) in both nTreg and iTreg cells stimulated by TGF-b plus TcR activation. 71 More recently, Smad3 phosphorylation has been shown to be inhibited by S1P1 signaling via the activation of the mTOR pathway to inhibit Treg cell differentiation and function. 81, 82 The inhibition of the mTOR pathway is now commonly used to selectively expand Treg cells over Teff cells; 42, 43 thus, this model of mTOR and Smad3 cross-talk can explain at least one aspect of how they cooperate to affect Treg cell function. Another molecule that upregulates Treg cell function is RA; RA induces the binding of the RA receptor and retinoid X receptor to a site at CNS1, which leads to local histone acetylation at the Smad3 binding site. Therefore, RA augments the TGF-b-dependent pathway and Treg cell induction by increasing the accessibility of Smad3 to the Foxp3 locus. 83 More recently, the inhibitor of DNA binding 3 was identified as a regulator of TGF-bdependent Foxp3 expression. Inhibitor of DNA binding 3 can relieve the inhibition of Foxp3 expression by reducing the binding of the transcription factor GATA-3 (see below) to the Foxp3 promoter, to allow for the enrichment and increased binding of transcription factor 3 (E2A). Furthermore, it was shown that inhibitor of DNA binding 3 À/À T cells were more prone to differentiate into Th17 cells but not into Foxp3 þ Treg cells. 89 The block in Foxp3 expression may be due to Stat6-mediated repression of Foxp3 transcription at its promoter region. 90 Luciferase reporter assays have supported the finding that GATA-3 can bind to the promoter of Foxp3, in order to mediate its transcriptional inhibition, and thus inhibit the differentiation of GATA-3 þ T cells into iTreg cells. 89 However, in nTreg cells, the low expression of Foxp3 seems to account for a degree of GATA-3 upregulation by some unclear intrinsic mechanism that favors nTreg-to-Th2 conversion. 46 A recent study by the same group analyzed the effect of GATA-3 depletion in Treg cells and found that these mice developed inflammatory disorder. 91 Here, GATA-3-deficient Treg cells expressed reduced amounts of Foxp3 and were enhanced in the ability to produce inflammatory cytokines. GATA-3 was also found to interact with the CNS2 region of the Foxp3 gene to promote its expression. Therefore, the role of GATA-3 to inhibit or increase Foxp3 expression could be determined by its interaction with Th2-or Treg cell-specific molecules, and seem to differ between iTreg and nTreg cells.
Runt-related transcription factor 1 (RUNX1)/acute myeloid leukemia 1 and RUNX3/acute myeloid leukemia 2 are also specifically involved in the process of Tcell lineage commitment. 92 The mRNA of RUNX1 and RUNX3, as well as FOXP3, can be upregulated by the stimulation of naïve T cells using anti-CD3/CD28 antibodies plus TGF-b treatment.
93 RUNX1 and RUNX3 can bind to the Foxp3 promoter in the presence of TGF-b to enhance the expression of Foxp3. The inactivation of the gene encoding for RUNX cofactor-core-binding factor-b in mice and the knockdown of RUNX1 and RUNX3 in human T cells reduces the expression of FOXP3 and the suppressive function of Treg cells. Another report also found that the RUNX-core-binding factor-b complexes can control the expression of Foxp3, and the evidence suggests that this complex acts at the CNS2 region. 69, 94 Thus, RUNX transcription factors are required for positively regulating FOXP3 expression and the function of Treg cells. 93 The nuclear factor (NF-kB) signaling pathway is a key regulator of Foxp3 expression; 69, 95, 96 c-Rel, an NF-kB family member, can bind to the Foxp3 enhancer region (CNS3) and control the development of Treg cells by promoting the formation of a Foxp3-specific enhanceosome. c-Rel-deficient mice have up to a 90% reduction of Treg cells compared with wild-type mice, and are compromised in Treg cell differentiation. 69, 95, 96 More recent studies have shown how the cooperative expression of c-Rel and JunB significantly enhances Foxp3 promoter activity, 97 and the role of RelA has also been observed to be important for iTreg cell differentiation in a CD28 signal-dependent manner. 98 
IL-2 and its receptor IL-2R are crucial for the expansion and survival of Foxp3
þ Treg cells in vivo. [99] [100] [101] When mice are deficient in the IL-2R-b gene, the number of Treg cells reduces remarkably, indicating that the signaling pathway downstream of IL-2 affects the differentiation of Treg cells. 99 Additionally, limiting the availability of IL-2 to Treg cells increases their propensity to convert into proinflammatory cells via the signals provided by inflammatory cytokines such as IL-12.
31 IL-2 can activate Stat5, which binds to the promoter of the Foxp3 gene to promote Treg cell differentiation by regulating the expression of Foxp3. 102, 103 Conversely, IL-6 stimulation leads to the binding of Stat3 to the CNS2 region to inhibit transcription, thus controlling Treg/Th17 polarization. 49, 104 The combination of IL-6 and TGF-b also induces the expression of the Th17 transcription factor RORgt, which can bind to the Foxp3 promoter to inhibit its transcription. 105 Other pathways which are involved in the direct regulation of the Foxp3 gene include the aryl hydrocarbon receptor, which can induce Foxp3 expression in Treg cells by binding to the conserved aryl hydrocarbon receptor-binding sites in the Foxp3 promoter. 106 The notch pathway has also been implicated in negatively controlling Foxp3 expression 107 through Hes1, which can interact with the promoter region of the Foxp3 gene 108 and also by signaling through the protein kinase C and canonical NF-kB pathways. 109 Finally, Bcl11b has also been shown to increase the suppressive nature of Treg cells, and was found to regulate the genes that encode Foxp3 and IL-10. 110 Histone modifications allow for the control of gene accessibility and may also regulate the transcription of Foxp3. The trimethylation of histone H3 lysine 4 (H3K4me3) is a permissive mark that facilitates the transcription of target genes, whereas the trimethylation of histone H3 lysine 27 (H3K27me3) inactivates them. Wei et al.
111 generated genome-wide H3K4me3 and H3K27me3 maps in naive, Th1, Th2, Th17, iTreg and nTreg cells, and found that the plasticity of Th cells was more flexible than that previously envisioned. For example, H3K27me3 was detected at the Il4 gene in naïve, Th1 and Th17 cells, whereas nTreg cells had little or no repressive marks in the Il4 gene. This indicates that Treg cells have a higher propensity for their induction into IL-4-secreting cells and, as mentioned above, have the increased plasticity to convert into Th2 cells. 46, 111 More importantly, the authors found no evidence of significant H3K27me3 marks in association with the Foxp3 promoter in all of the tested T-cell populations, which suggests that Foxp3 may be expressed more widely and transiently than previously thought.
As the current evidence shows, there are many transcription factors that can function positively or negatively at the Foxp3 gene to regulate Foxp3 expression. However, an extra level of regulation is exerted upon the Foxp3 gene through epigenetic means at the TSDR. Similar to Foxp3, transcription factors may confer either upregulatory or inhibitory effects on gene transcription dependent on the timing of their recruitment and the accumulation of other transcription modulators. In this sense, there is still a long way before we will fully understand the kinetics of how these transcription factors interact in vivo as multiple signals are received by Treg cells at any given time. The expression and 
Regulation of microRNA expression in FOXP3
þ Treg cells
The discovery and recent drive for the identification of microRNAs (miRNAs) [112] [113] [114] [115] [116] [117] that are involved in gene expression regulation has added a whole new dimension to our understanding of biological regulatory systems. miRNAs are small (B22 nucleotides) noncoding RNA molecules that can target partially complementary sequences primarily at the 3 0 -untranslated region of mRNAs, leading to their degradation or the prevention of translation. 118, 119 This ultimately results in the downregulation of protein expression. So far, more than 700 miRNAs have been identified in the human genome, whereby each miRNA has the ability to target and downregulate multiple mRNAs to create an overwhelming complex gene regulatory network. 118, 119 Unsurprisingly, miRNAs were found to be expressed in the hematopoietic system, 120 where they have been shown to have a broad role in regulating immunityextending to both the innate and adaptive arms of the immune system. [121] [122] [123] [124] In lymphocytes, miRNAs have been shown to determine their differentiation and function. 125 In this respect, the disruption of the RNaseIII Dicer-an endonuclease that facilitates miRNA maturation-in T and B cells causes a dramatic reduction in the numbers of thymocytes due to the increase in cell apoptosis. [126] [127] [128] [129] However, although Dicer is involved in the maturation of thymocytes, it does not affect CD4/ CD8 lineage commitment. 126 The disruption of Dicer specifically in the CD4 lineage using CD4-Cre Dicer fl/fl mice results in normal thymocyte numbers, a general reduction in T-cell numbers in the periphery, the induction of a Th1 bias 127, 130 and a substantial reduction of Treg cell numbers during their differentiation in the thymus. 127 IL-2 production is also highly dampened. 130 These peripheral conventional T cells are less able to express Foxp3 during in vitro stimulation in the presence of TGF-b, and the instability of Treg cells in this system leads to a late onset of colitis. 127 A more recent investigation into the disruption of Drosha (another RNAseIII enzyme related to miRNA biogenesis) in the CD4 T cell population has revealed a similar phenotype to the Dicer model described above. 131 Subsequent studies that utilized Foxp3-Cre mice to eliminate miRNA specifically in Treg cells via Dicer [131] [132] [133] and Drosha 131 have shown no disruption in their development but a reduction in their suppressive ability, as indicated by the presentation of fatal early-onset lymphoproliferative autoimmune syndrome. [131] [132] [133] Moreover, these mice display a similar phenotype to those that lack Foxp3 and/or are depleted of Treg cells. A milder and later onset of disease progression seen in the CD4-Cre-based disruption of miRNA 127, 130 may be attributed to the concurrent disruption of T-effector cell function. In the periphery, Rudensky and colleagues 132 observed a reduced number of Treg cells under non-inflammatory conditions; however, Treg cells could be activated to proliferate under inflammatory conditions but to the loss of suppressive capacity by the downregulation of Treg cell-specific effector molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and IL-10. Bluestone and colleagues 127, [131] [132] [133] found that peripheral Treg cells deficient in miRNA may adopt Th1-, Th2-and Treg cell like effector profiles, with a reduction of Foxp3 levels in Treg cells to confer this instability. These studies show a defined requirement of miRNAs for the differentiation and suppressive function of Treg cells, with the possibility that miRNA expression profiles may be indicative of Treg cell instability.
The Treg miRNA signature has been explored in mice 127 and humans 134 to reveal Treg-specific miRNA candidates for further functional analysis. In human Treg cells, miR-31 has been shown to bind to the 3 0 -untranslated region of FOXP3 mRNA for its downregulation, and miR-21 can positively-albeit indirectly-regulate FOXP3 expression. 134 The miR-31-low and miR-21-high signatures have also been shown in valproate-treated T cells in which the inhibition of histone deacetylases can induce FOXP3 expression through the induction of the transcription factor Ets-1; 77, 135 however, this miRNA signature was shown not to occur as a consequence of FOXP3 expression. 135 T-cell responses in miR-155-deficient mice are biased toward Th2 differentiation but not Th17 and Th1 effector responses, 124, 136, 137 and are protected against EAE, thus reflecting a role for miR-155 in the immune system. Rudensky and colleagues 132 have recently shown that miR-155-deficient Treg cells have impaired proliferation, and along with other independent investigators found miR-155 to be highly expressed in Foxp3 þ T cells and that Foxp3 can directly upregulate the expression of miR-155. 127, [138] [139] [140] Vigorito and colleagues 141 have also investigated the role of miR-155 in Treg cells and found that mice deficient in miR-155 have reduced numbers of Treg cells in the spleen and thymus, but their suppressive capacity, the expression of Treg markers and peripheral survival rate remained intact. Suppressor of cytokine signaling-1 protein expression is regulated by miR-155, which determines Treg cell responsiveness to IL-2 signaling. 140 The repression of suppressor of cytokine signaling-1 allows for Treg cell competitiveness in environments that are limited in the availability of IL-2.
140
A recent study using a Treg cell line HOZOT identified FOXO3a as a target for miR-155. 142 As Foxp3 is proposed to upregulate miR-155 expression by inducing its resident gene, and FOXO3a is a positive regulator of Foxp3 expression, this could provide a negative feedback of Foxp3 expression through miRNAs. Other studies have found that miR-142-3p can regulate adenyl cyclase 9 mRNA and the subsequent production of cAMP in Treg cells. 143 cAMP is a determinant of Treg cell suppressor function. 144, 145 Foxp3 mediates the downregulation of miR-142-3p expression, which has yet to be characterized as a direct or indirect process, to disrupt the maintenance of cAMP production. 143 Lu et al.
67
recently identified that mir-146a expression is crucial for Treg cell function, where miR-146a-mediated downregulation of Stat1 is required for Treg-mediated suppression of the Th1 response. 67 In this model, the expression level of Stat1 is crucial for Treg function, such that low Stat1 expression in Treg cells render them unable to mitigate Th1 responses, but excessive Stat1 þ regulatory T cell regulation and plasticity Y Gao et al activation due to the loss of mir-146a expression results in Treg cell instability and their reprogramming into Th1-like IFNg-secreting cells. 67 Furthermore, a recent analysis of miR-146a has revealed its major role in the dampening of inflammation and anti-tumor responses in mice. 146 Treg cells present a miRNA signature that is unique compared with conventional T cells; however, T cells with an induced overexpression of Foxp3 (and during their early activation) may also upregulate the expression Treg cell-specific miRNAs. 127 During autoimmune disease, an alteration in the miRNA signature of Treg cells has been identified between healthy and diseased patients. In multiple sclerosis, 23 miRNAs were found to be differentially expressed between diseased and healthy human subjects by array studies, where miR106b, miR-19b and miR-25 were upregulated in CD4 þ CD25 hi CD127 low Treg cells of multiple sclerosis patients. 147 During diabetes, an increased miR-510 and decreased miR-342 and miR-191 expressions were found in Treg cells of diseased patients compared with healthy controls. 148 In a mouse model of systemic lupus erythematosus, Divekar et al. 149 had an unexpected observation of a decrease in Dicer but an increase in miR-155 expression in Treg cells from diseased mice prone to systemic lupus erythematosus, which suggests the existence of a Dicer-independent miR-155 processing mechanism that precedes the onset of disease. Here, they found that 12 miRNAs increased and 54 reduced in Treg cells from diseased patients compared with healthy donor controls. 149 Our recent miRNA microarray studies have also identified similar patterns of miRNA expression in a Treg cell line as the studies above (unpublished data). These investigations bring a correlative expression of miRNA in diseased conditions, but whether or not miRNA profile changes arise as a contributor or as a consequence of inflammation require further investigation.
The discovery of Dicer/Drosha-independent miRNA processing by Argonaute 2 adds further complexity to the global role of miRNA in the immune system; this has yet to be investigated in Treg cells. [150] [151] [152] Combined with the invention of next-generation sequencing methods for the analysis of miRNA expression in the immune system, 153, 154 there remains a lot to be discovered before we can fully understand the role of different miRNAs in Treg cell function. Future studies of Treg cell miRNA signatures under different settings, such as cancer, infection and autoimmune disease, may provide clues into the intrinsic stability of Treg cells that lead to the development of disease. Other miRNAs that are important for Th cell function may also have a role in Treg cells when subjected to proinflammatory differentiation cues. Recent efforts have pursued to therapeutically target miRNAs in the immune system. Thus, the targeting of miRNAs specifically in Treg cells may also allow for the treatment of human diseases.
Dynamic regulation of the FOXP3 complex
FOXP3 is a key transcription factor required for the suppressive function of Treg cells. Upon the induction of FOXP3 expression in Treg cells, a number of inflammatory cytokines, such as IL-2 and IFN-g, are downregulated, whereas IL-10, CTLA-4, glucocorticoidinduced tumor necrosis factor receptor (TNFR)-related protein (GITR) and CD25 are upregulated. 99 Recent studies have suggested that FOXP3 does not function as a single molecule, but by forming a large supramolecular complex. 155, 156 Li et al. 155 detected an endogenous FOXP3 complex of more than 500 kD in size in human T cells, and found that FOXP3 may exist as homodimers or homotetramers. We propose that FOXP3 may determine the function and plasticity of Treg cells by interacting with different binding partners, and that the regulation of the FOXP3 complex is highly dynamic (Figure 1) .
FOXP3 protein contains a proline-rich region, zincfinger domain, leucine-zipper domain and a forkhead domain. In humans, FOXP3 is expressed as two isoforms; one is the full-length form representing an ortholog to murine Foxp3 and the other is a smaller form lacking exon 2 (amino acids 72-106 of the full-length form), which only exists in humans. Human T cells overexpressing FOXP3Dexon2 have an intermediate proliferative response to TcR stimulation and produce marginally more IL-2 than cells expressing only the full-length protein. 2 However, the distinct physiological function of FOXP3Dexon2 remains unclear. Ziegler and colleagues 157 have revealed that the RA receptor-RORa can interact with exon 2 of FOXP3 for the inhibition of RORa-mediated transcriptional activation. Moreover, FOXP3 may bind to the AF2 domain of RORa to downregulate the expression of IL-17, IL-22 and CXCR3, which shows that the high expression of FOXP3 in T cells can inhibit the expression of proinflammatory cytokines and subject them to differentiate into Treg cells.
However, the reverse effects of RORa on FOXP3 requires further investigation at the protein level. Additionally, Foxp3 can to be processed by convertases into a shorter form by its cleavage at the N and/or C terminals, which are functionally distinct from one another. 158, 159 NFAT binds cooperatively to composite DNA with AP-1 to regulate the expression of IL2, IL4 and IFN-g. NFAT is activated by calcium and calcineurin, whereas AP-1 is induced by the protein kinase C/Ras signal pathways. 160 , 161 Wu et al. 162 found that the FKH domain of FOXP3 could bind to NFAT at the same DNA region of the NFAT-AP-1 complex. They then proposed that FOXP3 could compete with the NFAT-AP-1 complex to repress the transcription of NFAT-AP-1 target genes. 162 In light of these findings, NFAT therefore displays bifunctional-like properties by binding to various transcription factors, and may affect the plasticity of T cells by acting like a switch in response to different stimuli. Recently, the structure of the NFAT1-FOXP3-DNA complex was solved. 163 These investigators found that the FKH domain of FOXP3 can form stable domain-swapped dimers in solution in the presence and absence of DNA. The interface of the domain-swapped dimer is important for the suppressive function of FOXP3, whereby the mutations at this interface eliminate FOXP3-mediated suppressive function. 163 As FOXP3 was earlier shown to form dimers via its leucine-zipper domain, 155, 164, 165 its dimerization therefore occurs at both the leucine-zipper and FKH domain. However, the question remains as to how the FKH domain is regulated by its interaction partners to allow for FOXP3-mediated suppression or induction of its target genes. Eos is a zinc-finger transcription factor that belongs to the Ikaros family, and a recently identified functional component of the Foxp3 complex that acts specifically to promote Foxp3-mediated target gene repression. 168 Eos is highly expressed in Treg cells, especially in activated Treg cells (CD4 þ CD25 hi CD62L lo ) and can bind to the proline-rich domain of Foxp3. The knockdown of Eos reverses Foxp3-mediated suppression of IL-2 expression, but has little effect on CD25, CTLA-4 and GITR expression. 168 Therefore, Eos is necessary for gene silencing but not for the expression of Foxp3-activated genes. The mechanism by which Eos is involved in Foxp3-dependent gene silencing may be through its corepressors such as C-terminal binding protein 1, which affects histone modification and promoter methylation involved in selective gene silencing. 168 Finally, FOXP3 has also been found to directly interact with c-Rel through its N-terminal region to repress the NF-kB pathway in mature Treg cells. 169 It is highly likely that FOXP3 has many other binding partners. We are currently investigating the role of various interaction partners of FOXP3 that were elucidated via the purification of the FOXP3 complex and by high-affinity in vitro protein-protein binding studies. Dissecting the interaction motifs of FOXP3 with its binding partners could allow for the targeting of these protein-protein interaction interfaces to block particular FOXP3-mediated pathways.
Post-translational modification and stability of FOXP3
Post-translational modifications are essential for the expression, location, stability and function of many functional proteins, including histones, transcription factors and other cellular proteins. [170] [171] [172] The different modes of protein post-translational modifications include acetylation, methylation, phosphorylation, ubiquitination, neddylation and sumoylation. These modifications may cross-talk and regulate one another synergistically; 173 currently, data is lacking as to the exact modifications that Foxp3 could undergo. The upstream signals that may lead to these modifications and the resultant downstream functions must also be dissected to fully understand these mechanisms in the context of Treg cell instability and plasticity. In addition, the post-translational modification of FOXP3 may affect a plethora of pathways, including the dynamic regulation of the FOXP3 complex and FOXP3 stability.
FOXP3 was recently identified as an acetylated protein in human primary CD4 þ CD25 þ Treg cells. 174 Both the histone acetyltransferase TIP60 and histone deacetylase HDAC7 can be recruited to the proline-rich domain of FOXP3, and are required for FOXP3-mediated suppression of IL-2 expression. 174 HDAC9 may also interact with FOXP3 in resting Treg cells, which can be disrupted by TcR stimulation and reversed by the pretreatment of Treg cells using the protein deacetylation inhibitor trichostatin A. 175 This suggests that the interactions between the components of the FOXP3 complex are highly dynamic and dependent on the circumstantial stimuli. The histone acetyltransferase p300 was recently identified for its ability to acetylate and stabilize Foxp3 protein. 176 This process can be reversed by the histone deacetylase SIRT1, which has been shown to colocalize with Foxp3 to mediate this process. [176] [177] [178] Impaired proteasomemediated Foxp3 degradation through the reduction of Foxp3 ubiquitination, combined with its hyperacetylation, can increase the suppressive function of Treg cells 176 and affect target gene occupancy of Foxp3; 175, 179 however, this could be perturbed under the influence of Treg celldestabilizing cytokines such as IL-6. 180 We have recently identified a stress-signal-activated E3 ubiquitin ligase, named STUB1, that can interact with FOXP3 to promote its polyubiquitination and degradation in vitro and in vivo, whereby the overexpression of STUB1 in Treg cells impairs their suppressive function (unpublished data). This process is linked to the heat-shock response of Treg cells, which may indicate the role of heat and/or the combination of proinflammatory signals to downregulate FOXP3 expression in Treg cells and allow for their conversion into proinflammatory cells (unpublished data).
Post-translational modification is a truly efficient and dynamic process. Our knowledge in this research field in the context of FOXP3 is still very limited. Modifications such as phosphorylation, sumoylation and neddylation have not been reported but are currently being investigated in our lab, and the distinct sites of acetylation and ubiquitination, regulation of different HATs and HDACs, and their corresponding upstream signaling pathways remain unclear. How these post-translational changes in FOXP3 regulate its target gene expression and its own stability would be of high interest to the Treg cell instability field as a means of finding new drug targets to therapeutically manipulate Treg cells to suit our requirements. 
Conclusions
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